Very early researchEnded earlyNCT04102618What this trial is testingA Window-of-opportunity Study of Pelareorep in Early Breast CancerWho this might be right forBreast Cancer Oncolytics Biotech 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225What this trial is testingPhase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label TrialWho this might be right forBreast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Not applicableLooking for participantsNCT07214532What this trial is testingSignatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerWho this might be right forBreast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement) Natera, Inc. 725
Not applicableLooking for participantsNCT06106477What this trial is testingImpact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast CancerWho this might be right forBreast Cancer Medical College of Wisconsin 20
Not applicableStudy completedNCT06619704What this trial is testingObservational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With ChemotherapyWho this might be right forMetastatic Breast Cancer Novartis Pharmaceuticals 194
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287What this trial is testingSHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyWho this might be right forSHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625What this trial is testingNeoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer PatientsWho this might be right forUntreated Early-stage or Locally Advanced Breast Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Not applicableLooking for participantsNCT06050109What this trial is testingThe Benefits of Continued Use of Ovarian Function Suppression After 5 YearsWho this might be right forBreast Cancer FemaleEndocrine Therapy Hongmei Zheng, PhD 1,200
Testing effectiveness (Phase 2)Ended earlyNCT01919229What this trial is testingA Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)Who this might be right forEarly Breast Cancer Novartis Pharmaceuticals 14
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07305246What this trial is testingClinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast CancerWho this might be right forBreast Cancer First Hospital of China Medical University 120
Post-approval studies (Phase 4)UnknownNCT05809024What this trial is testingSelect the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine TherapyWho this might be right forLocally Advanced Breast CancerHormone Receptor Positive，HER2-negative Breast Cancer Yongsheng Wang 100
Not applicableNot Yet RecruitingNCT07215364What this trial is testingImpact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 InhibitorsWho this might be right forEarly-stage Breast Cancer Spanish Breast Cancer Research Group 74
Testing effectiveness (Phase 2)Active Not RecruitingNCT04293393What this trial is testingNeoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer PatientsWho this might be right forEarly Breast Cancer Spanish Breast Cancer Research Group 200
Not applicableLooking for participantsNCT07531693What this trial is testingPatient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast CancerWho this might be right forHR+/HER2- Early Breast Cancer Institut fuer Frauengesundheit 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07292207What this trial is testingAbemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast CancerWho this might be right forctDNA MonitoringBreast Cancer Nagoya City University 30
Large-scale testing (Phase 3)Ended earlyNCT05128773What this trial is testingStudy of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityWho this might be right forBreast Cancer Sanofi 3
Testing effectiveness (Phase 2)Study completedNCT05549505What this trial is testingA Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryWho this might be right forBreast Cancer Arvinas Inc. 152
Early research (Phase 1)Looking for participantsNCT06139107What this trial is testingRADIANT: Pre-op Radiation With Abemaciclib and LetrozoleWho this might be right forBreast Cancer Mridula George, MD 15
Not applicableNot Yet RecruitingNCT07484763What this trial is testingPredicting Recurrence in HR+/HER2- Early Breast CancerWho this might be right forBreast Cancer, HR+/HER2- Early-Stage Shengjing Hospital 500
Large-scale testing (Phase 3)Not Yet RecruitingNCT05889871What this trial is testingA Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast CancerWho this might be right forHR+/HER2-breast Cancer Fudan University 916